Evaluation of effect of hybrid bioartificial liver using end-stage liver disease model

Table 3 Changes of MELD score before and after treatment of HBL

Patients	Before-treatment						After-treatment
	1	2	3	4	5	mean ± SD	1	2	3	4	5	mean ± SD
PTA%	22.4	21	18	11	14.37	17.35 ± 4.7	40.2	43	45	30.1	18.2	35.3 ± 20.87
INR	2.42	2.51	2.61	4.14	3.74	3.08 ± 1.27	1.58	1.55	1.5	2.08	2.71	1.8 ± 1.02
Creatinine (mg/dL)	13	16.9	7.9	16.6	42.4	19.36 ± 15.3	5.9	5	4.3	8.9	35.2	11.8 ± 13.1
Bilirubin (mg/dL)	20.4	17	15.1	22.2	40.46	23.03 ± 10.1	20.4	17	15.1	22.2	40.46	17.4 ± 12.66
MELD	41	41	41	47	48	43.6	34	33	32	39	45	33.6